Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADRB1 | P08588 | 4/20 | 0.51 |
| ▸ | HIF1A | Q16665 | 3/20 | 0.51 |
| ▸ | LMNA | P02545 | 2/20 | 0.51 |
| ▸ | ADRB2 | P07550 | 7/20 | 0.44 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | NFKB1 | P19838 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.37 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 1/20 | 0.37 |
| ▸ | CASP7 | P55210 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | BLM | P54132 | 1/20 | 0.37 |
| ▸ | ADRB3 | P13945 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22864191 | 0.85 | ADRB1 (0.35) | ADRB1HIF1ALMNAADRB2CYP2D6 | |
| SCHEMBL23311674 | 0.80 | AOC3 (0.37) | LMNACASP7 | |
| SCHEMBL24630901 | 0.80 | HIF1A (0.47) | ADRB1HIF1ALMNAADRB2CYP2D6 | |
| SCHEMBL21605732 | 0.78 | AOC3 (0.35) | CYP3A4 | |
| SCHEMBL21603252 | 0.75 | PTGS1 (0.36) | CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL30134146 | 0.75 | PTGS1 (0.36) | CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL24630982 | 0.72 | ADRB2 (0.50) | ADRB1ADRB2TSHRKMT2AADRB3 | |
| SCHEMBL11730637 | 0.72 | HIF1A (0.50) | ADRB1HIF1ALMNAADRB2CYP2D6 | |
| SCHEMBL23554439 | 0.71 | CYP3A4 (0.36) | CYP2D6CYP3A4CYP2C9 | |
| SCHEMBL10840859 | 0.70 | HIF1A (0.69) | ADRB1HIF1ALMNAADRB2CYP2D6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | CURASEN THERAPEUTICS, INC. | 2022-10-06 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20220315534-A1 | BETA ADRENERGIC AGONIST AND METHODS OF USING THE SAME | ADRB2, ADRB1, ADRA2C | ADRB1 2/4885HIF1A 2371/4885LMNA 1389/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.